louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT03272035: General Practitioners' Felt With Their Patients' Death (REGIDAQ)
Official title: General Practitioners' Felt With Their Patients' Death (REGIDAQ)
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Death
Keywords: General practice
death
bereavement
Lead sponsor: University Hospital, Limoges
Sponsor class: OTHER
First posted: 2017-09-05
Enrollment: 481
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: OTHER
Time perspective: CROSS_SECTIONAL
Sampling method: NON_PROBABILITY_SAMPLE
Study population: General practitioners from the Nouvelle Aquitaine region

Brief summary: Very few studies are dealing with the way general practitioners feel the death of their patients. Main studies about that subject are qualitative. It needs quantitative studies to analyse how is felt general practitioners' patients' death. This is an epidemiologic quantitative cross-sectional study. The Studied population is the whole of the general practitioners of the region Nouvelle-Aquitaine. The primary endpoint is the percentage of the general practitioners which have hard time living with their patients' death. The secondary endpoints are to evaluate the general practitioners' help needing after their patients' death, to evaluate the personal and professional impact of the patient's death, the percentage of general practitioners using chemical aid after their patients' death and to determinate the existence of support facilities to help general practitioners to stand patients' death. The results of that study could help general practitioners to improve their medical practice in the patient's death situation.


Eligibility criteria: Inclusion Criteria:

* General practitioners from the Nouvelle-Aquitaine region.
* Exclusive or joint exercise of general medicine.
* None retired

Exclusion Criteria:

* Retired patricians
* Students, Residents
* General practitioners from another region
* General practitioners with no general medicine activity

Primary outcomes:
measure: percentage of hard time living
timeFrame: 2 months (End of study)
Secondary outcomes:
measure: percentage of help needing
timeFrame: 2 months (End of study)
measure: percentage of personal impact
timeFrame: 2 months (End of study)
measure: percentage of professional impact
timeFrame: 2 months (End of study)
measure: percentage of chemical aid using
timeFrame: 2 months (End of study)
measure: support facilities
timeFrame: 2 months (End of study)
Other outcomes:
Locations:
city: Limoges
country: France
facility: University Hospital
Study officials:
affiliation: University Hospital, Limoges
name: Karen Rudelle, doctor
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT02180035: Treatment With Nutritional Eating Plan and Dietary Fibers in Adult Patients With HIV/AIDS
Official title: Effect of Treatment Nutritional With Supplementation About Biochemical Profile and Anthropometry in Adult Patients With HIV/AIDS
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dietary Modification
Dyslipidemia
Signs and Symptoms, Digestive
HIV
Keywords: diet therapy
symbiotic
dyslipidemia
gastrointestinal symptoms
body composition
adherence
HIV
HAART
Lead sponsor: Conselho Nacional de Desenvolvimento Científico e Tecnológico
Sponsor class: OTHER_GOV
First posted: 2014-07-02
Enrollment: 290
Sex: ALL
Minimum age (years): 19
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: To evaluate if nutritional treatment with nutritional supplementation of dietary fiber reduces cholesterol levels and triglycerides (dyslipidemia) in patients with HIV/AIDS receiving antiretroviral therapy (HAART).


Eligibility criteria: Inclusion Criteria:

* HIV-infected patients
* Adults (≥ 19 years old)
* On highly active antiretroviral therapy (HAART)

Exclusion Criteria:

* Pregnancy
* Breastfeeding
* Opportunistic disease

Primary outcomes:
measure: Seric lipid levels
timeFrame: Baseline, Week 24
Secondary outcomes:
measure: Fasting blood glucose
timeFrame: Baseline, Week 24
measure: Gastrointestinal symptoms
timeFrame: Baseline, Week 24
measure: Adherence to the nutritional intervention and nutritional appointments
timeFrame: Baseline, Week 24
measure: Body composition
timeFrame: Baseline, Week 24
measure: Anthropometric measures
timeFrame: Baseline, Week 24
Other outcomes:
Locations:
city: Goiânia
country: Brazil
facility: Outpatient Infectoparasitary Diseases, Hospital das Clinicas, Federal University of Goiás
state: Goiás
Study officials:
affiliation: Federal University of Goiás
name: Marianne O Falco, MSc
role: PRINCIPAL_INVESTIGATOR
affiliation: Federal University of Goiás
name: Erika A Silveira, PhD
role: STUDY_DIRECTOR
References:
citation: Falco M, Castro Ade C, Silveira EA. [Nutritional therapy in metabolic changes in individuals with HIV/AIDS]. Rev Saude Publica. 2012 Aug;46(4):737-46. doi: 10.1590/s0034-89102012005000050. Epub 2012 Jul 10. Portuguese.
citation: Nery MW, Martelli CM, Silveira EA, de Sousa CA, Falco Mde O, de Castro Ade C, Esper JT, Souza LC, Turchi MD. Cardiovascular risk assessment: a comparison of the Framingham, PROCAM, and DAD equations in HIV-infected persons. ScientificWorldJournal. 2013 Oct 21;2013:969281. doi: 10.1155/2013/969281. eCollection 2013.
citation: Santos ASEAC, Silveira EAD, Falco MO, Nery MW, Turchi MD. Effectiveness of nutritional treatment and synbiotic use on gastrointestinal symptoms reduction in HIV-infected patients: Randomized clinical trial. Clin Nutr. 2017 Jun;36(3):680-685. doi: 10.1016/j.clnu.2016.06.005. Epub 2016 Jun 23.
Clinical trial NCT04148235: A Pilot Study to Explore the Role of Gut Flora in Celiac Disease
Official title: A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Celiac Disease
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Celiac Disease
Lead sponsor: ProgenaBiome
Sponsor class: OTHER
First posted: 2019-11-01
Enrollment: 0
Sex: ALL
Standard ages: CHILD
ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Observational model: CASE_ONLY
Time perspective: PROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: Patients diagnosed with Celiac Disease

Brief summary: This study seeks to correlate microbiome sequencing data with information provided by patients and their medical records regarding Celiac Disease.

Detailed description: The goal of this Research Study is to better understand how the genetic information in subject's microbiome correlates to the information provided in surveys and in medical records regarding Celiac Disease

Eligibility criteria: Inclusion Criteria:

1. Signed informed consent, demonstrating that the patient understands the procedures required for the study and the purpose of the study
2. Male or female patients of any age (interest is given to children to compare with mothers).
3. Diagnosis of Celiac Disease

Exclusion Criteria:

1. Refusal to sign informed consent form
2. History of bariatric surgery, total colectomy with ileorectal anastomosis or proctocolectomy.
3. Postoperative stoma, ostomy, or ileoanal pouch
4. Participation in any experimental drug protocol within the past 12 weeks
5. Treatment with total parenteral nutrition
6. Any clinically significant evidence of disease that could interfere with the subject's ability to enter the trial
7. Inability to adequately communicate with the investigator or their respective designee and/or comply with the requirements of the entire study

Primary outcomes:
measure: Correlation of Microbiome to Celiac Disease via Relative Abundance Found in Microbiome Sequencing
timeFrame: One year
Secondary outcomes:
measure: Validation of Sequencing Methods
timeFrame: One year
Other outcomes:
Locations:
city: Ventura
country: United States
facility: ProgenaBiome
state: California
Study officials:
affiliation: ProgenaBiome
name: Sabine Hazan, MD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06732635: Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer
Official title: Enhanced Recovery After Surgery (ERAS) for Laparoscopic Hysterectomy at Low Risk Endometrial Cancer: A Randomized Controlled Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE3
Conditions: Endometrial Cancer
Lead sponsor: Fundacion para la Formacion e Investigacion Sanitarias de la Region de Murcia
Sponsor class: OTHER
First posted: 2024-12-13
Enrollment: 68
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: A controlled, randomized, parallel-group, open-label, interventional, single-center clinical trial in which the intervention group will be managed according to the multimodal rehabilitation protocol (RICA clinical pathway), and the control group will receive traditional care that has been provided up to now.
Primary purpose: TREATMENT

Brief summary: Enhanced recovery after surgery (ERAS) programs are designed to achieve early recovery after surgery and a shorter length of stay (LOS) at hospital.

So far there are only three prospective, randomised studies that exclusively analyze patients affected by oncogynecological pathology providing a high level of scientific evidence. To our knowledge, no studies have been conducted specifically on ERAS pathways in endometrial cancer treated by laparoscopy. This study aims to evaluate whether ERAS pathways are beneficial for patients with endometrial cancer, particularly among low-risk early endometrial cancer operated by laparoscopy. Length of stay (LOS), perioperative morbidity and mortality, and perioperative quality of life were analyzed comparing both ERAS and Conventional protocols groups.


Eligibility criteria: Inclusion Criteria:

* Patients undergoing laparoscopic hysterectomy for stage 1A and 1B endometrial cancer

Exclusion Criteria:

* Age under 18 years
* ASA IV
* Liver cirrhosis
* Psychiatric illness
* Urgent surgery
* The patient's desire not to participate.

Primary outcomes:
measure: Lengh of stay
timeFrame: 30 days after surgery
measure: Day of discharge
timeFrame: 30 days after surgery
measure: Readmisión
timeFrame: During 1st month after surgery
Secondary outcomes:
Other outcomes:
measure: Complications
timeFrame: 30 days after surgery
measure: Quality of life (QoL)
timeFrame: Preoperative, 3, 10 and 30 days after surgery
measure: Level of Pain
timeFrame: Preoperative, 3, 10 and 30 days after surgery
Locations:
city: Murcia
country: Spain
facility: Hospital Clínico Universitario Virgen de la Arrixaca
Study officials:
References:
Clinical trial NCT02657135: Targeted Evaluation, Action, & Monitoring of Traumatic Brain Injury
Official title: Targeted Evaluation, Action, & Monitoring of Traumatic Brain Injury
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Traumatic Brain Injury (TBI)
Lead sponsor: University of Pittsburgh
Sponsor class: OTHER
Collaborators: name: United States Department of Defense
First posted: 2016-01-15
Enrollment: 95
Sex: ALL
Minimum age (years): 18
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: TEAM-TBI (Targeted Evaluation, Action, and Monitoring of Traumatic Brain Injury) is a research study that brings together TBI patients, advanced evaluation methods, and experts in a multi-faceted study to address the heterogeneity of TBI and to evaluate the effects self-help strategies might have on TBI outcomes.

Detailed description: TEAM-TBI (Targeted Evaluation, Action, and Monitoring of Traumatic Brain Injury) proposes a new approach to clinical trials in TBI that will:

* Evolve diagnostic technology \& treatment
* Improve self-help strategies
* Lower cost and speed for delivery of effective strategies

The TEAM-TBI program proposes an innovative new approach to TBI clinical trials to overcome the limitations of past efforts and achieve long-awaited breakthroughs for TBI survivors. The study will involve a comprehensive 3-4 day intake evaluation, followed by a variety of remotely performed tasks during a 1-6 month follow-up period.

Eligibility criteria: Inclusion Criteria:

* 18-60 years of age
* Fluent in English
* Documented history of TBI or blast exposure since 2001

Exclusion Criteria:

* Inability to have MRI
* Pregnancy
* History of TIA within last 6 months.
* Presently involved in open litigation

Primary outcomes:
measure: The main outcome variable in the study will be the change in Post-Concussion Symptom Scale (PCSS) score from the initial intake evaluation compared to last follow-up evaluation.
timeFrame: Up to 6 months
Secondary outcomes:
measure: Change in the Satisfaction with Life Scale
timeFrame: Up to 6 months
Other outcomes:
Locations:
city: Pittsburgh
country: United States
facility: University of Pittsburgh Neurotrauma Clinical Trials Center
state: Pennsylvania
Study officials:
References:
Clinical trial NCT02100735: Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients
Official title: Evaluation of an Analgosedation Protocol in Mechanically Ventilated Patients
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Effect of Protocolized Sedation on Days of Mechanical Ventilation in the ICU
Keywords: sedatives
analgesics
protocol
mechanical ventilation
analgosedation
Lead sponsor: Tampa General Hospital
Sponsor class: OTHER
First posted: 2014-04-01
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Maximum age (years): 100
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: HEALTH_SERVICES_RESEARCH

Brief summary: The purpose of this study is to evaluate how the investigators provide sedation (medicine that make you sleepy) in the investigators intensive care unit (ICU). This study will look at a new way of using sedation in the ICU to see what effect it has on patients and if it decreases the amount of time spent on mechanical ventilation (machine that breathes for you), and in the ICU.


Eligibility criteria: Inclusion Criteria:

* Patients 18 years of age and older
* Patients expected to require mechanical ventilation for greater than 48 hrs

Exclusion Criteria:

* Need for continuous neuromuscular blockade
* Severe chronic neurocognitive dysfunction
* Tracheostomy at the time of study enrollment
* Alcohol withdrawal risk or symptoms
* Drug overdose
* Chronic use of narcotics
* Active seizures

Primary outcomes:
measure: Days on mechanical ventilation
timeFrame: Participants will be assessed daily for the duration of their stay in the ICU, an expected average of 4-5 days
Secondary outcomes:
measure: ICU Length of stay
timeFrame: Participants will be followed for the entire length of their ICU stay, expected average of 4-7 days
measure: 28 day mortality
timeFrame: Participants will be followed for 28 days from enrollment into the study
Other outcomes:
Locations:
city: Riverview
country: United States
facility: Beatrice Adams
state: Florida
Study officials:
References:
Clinical trial NCT00194935: Weekly Topotecan Therapy in Patients With Ovarian Cancer
Official title: A Phase II Trial of Weekly Topotecan As Consolidation Therapy in Ovarian Cancer Patients After Initial Chemotherapy
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE2
Conditions: Ovarian Cancer
Keywords: Ovarian Cancer
Cancer of the Ovary
Lead sponsor: Weill Medical College of Cornell University
Sponsor class: OTHER
First posted: 2005-09-19
Enrollment: 32
Sex: FEMALE
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: The purpose of this study is to find out the safety and feasibility of weekly topotecan consolidation therapy in patients with ovarian cancer.

Detailed description: Patients with Stage IIIC and IV optimally-debulked ovarian cancer will be treated with 6 cycles (every 3 weeks) of carboplatin (AUC 5) and paclitaxel (175 mg/m2). Patients who demonstrate a complete clinical response to this regimen will then be treated with topotecan consolidation (4 mg/m2 weekly x 8 weeks for one cycle followed by a break in the 9th week) for a maximum of 3 cycles. Primary endpoints will be toxicity and the determination of the appropriate dose, schedule, and duration of topotecan for further consolidation trials.

Eligibility criteria: Inclusion Criteria:

* Patients must have a histopathologic diagnosis of epithelial ovarian cancer.
* Patients must have completed front-line chemotherapy and be clinically NED (CA 125 \<35, negative CT scan, negative physical exam).
* Patients may have a second look laparoscopy, however, there must be no gross disease present (microscopic disease or pathologically negative).
* Patients must not have had other myelosuppressive therapy within four weeks of initiating topotecan therapy.
* Topotecan treatment must begin within 10 weeks following last cycle of initial chemotherapy.
* Patients may have had only one prior chemotherapy regimen.

Exclusion Criteria:

* Patients with a concomitant malignancy other than squamous cell or basal cell skin cancer.
* Patients who are pregnant or breast-feeding.

Primary outcomes:
measure: The objective of this study is to evaluate the safety and feasibility of weekly topotecan consolidation therapy in patients with epithelial ovarian cancer.
Secondary outcomes:
measure: To determine the efficacy (Progression free survival) of weekly topotecan as consolidation therapy in ovarian cancer patients who are clinically NED or have microscopic disease only after first-line chemotherapy.
Other outcomes:
Locations:
city: New York
country: United States
facility: Weill Medcial College of Cornell University
state: New York
Study officials:
affiliation: Weill Medical College of Cornell University
name: Thomas Caputo, M.D.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT06515535: Efficacy of Topical Tranexamic Acid in Reducing Blood Loss During CS in Patients With Placenta Previa
Official title: Efficacy of Topical Tranexamic Acid in Reducing Blood Loss During Elective Cesarean Delivery in Patients With Placenta Previa
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Placenta Previa
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2024-07-23
Enrollment: 56
Sex: FEMALE
Minimum age (years): 20
Maximum age (years): 40
Standard ages: ADULT
Accepts healthy volunteers: yes
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Objectives: To evaluate the efficacy of topical tranexamic acid applied on the placental bed after placental delivery to reduce blood loss during cesarean delivery in women with placenta previa.

Patients will be randomly assigned into two groups:

Group (A) - Study group (n=28): The topical tranexamic acid group will receive topical tranexamic acid after placental delivery applied on the placental bed for 5 minutes by using a sterile towel soaked with 2g tranexamic acid (Kapron, Amoun, Cairo, Egypt) (4 ampules 500ug) diluted in 100ml of sodium chloride 0.9%, in addition to the IV infusion of 1g tranexamic acid (2 ampules 500ug) diluted with 20ml of 5% glucose administered just after delivery of the fetus.

Group (B) - Control group (n=28): The intravenous tranexamic acid group will receive only an IV infusion of 1g of tranexamic acid (2 ampules 500ug) diluted with 20 ml of 5% glucose administered just after delivery of the fetus.


Eligibility criteria: Inclusion Criteria:

* Age: 20-40 years old.
* BMI less than 30 kg/m2.
* Pregnancy of singleton living fetus.
* Placenta previa by ultrasound assessment
* Gestational age \> 36 weeks.

Exclusion Criteria:

* Women with a history of any medical disorder with pregnancy, e.g., Gestational diabetes and hypertension.
* Women with systemic diseases, e.g., diabetes mellites, systemic immune disorders such as systemic lupus erythematosus
* Women with bleeding tendency or coagulopathy.
* Women on anticoagulants or hemodynamically unstable women.
* Women with uterine abnormalities, such as fibroids or polyps.
* Emergency termination of pregnancy.
* Intrauterine fetal death.
* Pregnancy with obstetric hemorrhage, e.g., antepartum hemorrhage
* Cases of placenta accrete spectrum disorder or placental abruption
* Women with known allergies to Tranexamic acid

Primary outcomes:
measure: Amount of blood loss
timeFrame: during operation
Secondary outcomes:
measure: operative time
timeFrame: during operation
Other outcomes:
Locations:
Study officials:
References:
Clinical trial NCT03494335: Online Surveys to Assess the Perception and Performance of Imaging and Associated Aspects
Official title: Online Surveys to Assess the Perception and Performance of Imaging Associated Aspects
Study type: OBSERVATIONAL
Overall status: WITHDRAWN
Conditions: Perception of Imaging
Lead sponsor: University of Cincinnati
Sponsor class: OTHER
First posted: 2018-04-11
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: yes
Observational model: COHORT
Time perspective: RETROSPECTIVE
Sampling method: NON_PROBABILITY_SAMPLE
Study population: The study population consists of volunteers agreeing to complete the survey tool. It is anticipated that the surveys will be completed by participants that can be considered stakeholders, such as physicians, technologist's physicists, imaging scientists, administrative staff, or others with interest in the topic.

Brief summary: In this exploratory study, the researchers would like to investigate the background, perception, current use practices, potential unmet needs and/or challenges in regard to imaging procedures, imaging technology, or any other aspect related to the broader field of imaging.

Detailed description: The researchers plan to include volunteer participants to complete these surveys. The goal of these exploratory efforts will be to increase the currently very limited information available in the topics of interest stated above, and the findings, even if only from limited group of respondents, will help guide research development, prepare for design of clinical trials, guide special interest groups, and serve as role data for appropriate scientific publications.

Eligibility criteria: Inclusion Criteria:

* Male and female participants who have access to the online survey tool and can read and write in English

Exclusion Criteria:

* None, as this is voluntary

Primary outcomes:
measure: Perception of PET/CT imaging agent Y-90
timeFrame: through study completion, on average 2-5 years
measure: Perception of PET/CT imaging agent NaF
timeFrame: through study completion, on average 2-5 years
measure: Perception of MRI contrast agents
timeFrame: through study completion, on average 2-5 years
Secondary outcomes:
Other outcomes:
Locations:
city: Columbus
country: United States
facility: Martha Morehouse Medical Plaza
state: Ohio
Study officials:
affiliation: Ohio State University
name: Michael V Knopp, MD, PhD
role: PRINCIPAL_INVESTIGATOR
References: